|
 |
LEADERSHIP IN FIBROSIS: Preclinical Efficacy Models
Promedior and its collaborators have demonstrated the ability of Pentraxin-2 to block the development of fibrosis in several validated models of fibrotic disease, across all major tissue types, confirming its potential as a novel anti-fibrotic agent.
Preclinical Models in which PTX-2 Has Demonstrated Efficacy
|
|
|
| Eye |
Photorefractive Keratectomy surgery (PRK) |
Rabbit |
| Proliferative Vitreoretinopathy (PVR) |
Rabbit |
| Trabeculectomy |
Rabbit |
| Laser-induced CNV |
Mouse |
| Retinopathy of Prematurity |
Mouse |
| Rho-VEGF Transgenic |
Mouse |
| Dry Eye |
Mouse |
|
|
| Lung |
Bleomycin |
Rat, Mouse |
| TGF-ß |
Mouse |
| Severe Asthma |
Mouse |
| Acute Asthma |
Mouse |
|
|
| Kidney |
Ureter Obstruction |
Rat, Mouse |
| Ischemia/Reperfusion |
Mouse |
|
|
| Skin |
Hypertrophic Scar |
Pig, Mouse, Rat |
|
|
| Heart |
Ischemia/Reperfusion |
Mouse |
|
|
| Liver |
Carbon Tetrachloride |
Mouse |
| Bile duct ligation |
Mouse |
|
|
| GI (bowel) |
Radiation-induced injury |
Rat |
|
|
| Oral Mucosa |
Radiation-induced injury |
Hamster |
|
|
[ back to top ]
|
|
|
